Indianapolis Business Journal

Eli Lilly and Co. once was a pioneer in biotech drugs and treating autoimmune diseases, but abandoned the fields in 1991. Subsequently, biotech autoimmune medicines have become best-sellers. This week, J.K. Wall details how Lilly has been trying to get back in the game. Also this week, Anthony Schoettle reports the Indianapolis Indians' stock buy-back offer might be undervaluing the franchise. And in A&E Etc., Lou Harry reviews Bar Rio.